- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 1, 1999
Highlights
- Market Cap
- $9.02M
- Enterprise Value
- -$4.04M
- EPS (TTM)
- -$1.86
- Total Revenue (TTM)
- $170.00K
- Gross Profit (TTM)
- $155.00K
- EBITDA (TTM)
- -$11.88M
- Year Range
- $0.99 - $5.07
- ROA (TTM)
- -116.30%
- ROE (TTM)
- -149.65%
- Avg. Volume (1M)
- 111K
- Avg. Volume Value (1M)
- $240.85K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
LSTA Performance Chart
Lisata Therapeutics Inc. (LSTA) is down 46.8% since the beginning of the year. At $1 per share, LSTA is trading 80.5% below its 52-week high of $5. Investors who bought $1,000 worth of LSTA shares 5 years ago would now be looking at an investment worth $50.
Loading charts...
Compare this symbol against anything
Returns By Period
Lisata Therapeutics Inc. (LSTA) has returned -46.77% so far this year and -60.24% over the past 12 months. Over the last ten years, LSTA has returned -36.14% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Lisata Therapeutics Inc.
- 1D
- -3.88%
- 1M
- -70.27%
- 6M
- -78.62%
- YTD
- -46.77%
- 1Y
- -60.24%
- 3Y*
- -32.37%
- 5Y*
- -45.15%
- 10Y*
- -36.14%
- ALL TIME*
- -35.86%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
LSTA Monthly Returns History
Based on dividend-adjusted daily data since Mar 1, 1999, LSTA's average daily return is +0.17%, while the average monthly return is +0.32%. At this rate, an investment would double in approximately 18.1 years.
Historically, 39% of months were positive and 61% were negative. The best month was Feb 2003 with a return of +166.7%, while the worst month was Jul 2026 at -70.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, LSTA closed higher 38% of trading days. The best single day was Feb 12, 2003 with a return of +150.0%, while the worst single day was May 4, 2005 at -60.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 148.92% | -11.45% | 22.20% | -37.72% | 4.17% | 4.62% | -70.88% | -46.77% | |||||
| 2025 | -16.09% | -4.82% | -1.26% | 0.85% | 10.14% | 11.06% | -14.46% | -6.45% | 12.93% | 6.49% | -26.16% | -9.71% | -37.58% |
| 2024 | -9.52% | 18.62% | 6.48% | -12.50% | 7.69% | 18.03% | -7.33% | -11.68% | 5.63% | -5.67% | -2.47% | 7.97% | 9.16% |
| 2023 | 41.50% | -11.73% | 2.69% | 0.15% | 26.15% | -9.76% | -14.32% | -31.23% | -1.83% | 1.40% | 0.92% | 24.66% | 7.91% |
| 2022 | -7.94% | -9.40% | 2.85% | -28.74% | -1.85% | 4.97% | -5.64% | -1.84% | -37.14% | -8.42% | -17.45% | -27.71% | -79.96% |
| 2021 | 48.25% | -16.04% | 8.43% | -15.54% | -6.75% | 5.92% | -17.39% | -1.50% | -6.87% | -5.74% | -18.46% | -10.25% | -41.15% |
Benchmark Metrics
Lisata Therapeutics Inc. has an annualized alpha of 48.21%, beta of 0.46, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since March 01, 1999.
- This stock participated in 158.42% of S&P 500 Index downside but only -36.44% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.46 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 48.21%
- Beta
- 0.46
- R²
- 0.00
- Upside Capture
- -36.44%
- Downside Capture
- 158.42%
Return for Risk
Risk / Return Rank
LSTA ranks 15 for risk / return — above 15% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Lisata Therapeutics Inc. (LSTA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LSTA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.92 | ||
| Sortino ratioReturn per unit of downside risk | -2.47 | ||
| Omega ratioGain probability vs. loss probability | 0.92 | 1.25 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | -0.75 | 2.00 | -2.75 |
| Martin ratioReturn relative to average drawdown | -2.19 | 8.49 | -10.68 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Lisata Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Lisata Therapeutics Inc. was 100.00%, occurring on Jul 31, 2026. The portfolio has not yet recovered.
The current Lisata Therapeutics Inc. drawdown is 100.00%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-100.00%Jul 2026 | 26y 6mo | — | 26y 6moJan 2000 - now | — |
-39.58%Nov 1999 | 6mo 3d | 1mo 6d | 7mo 9dMay 1999 - Dec 1999 | — |
-26.83%Dec 1999 | 1d | 13d | 14dDec 1999 - Jan 2000 | — |
-25.00%Apr 1999 | 7d | 10d | 17dApr 1999 - Apr 1999 | — |
-18.18%Apr 1999 | 1mo | 2d | 1mo 2dMar 1999 - Apr 1999 | — |
Drawdown Indicators
| LSTA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -80.36% | -9.10% | -71.26% |
Max Drawdown (3Y)Largest decline over 3 years | -80.36% | -18.90% | -61.46% |
Max Drawdown (5Y)Largest decline over 5 years | -95.04% | -25.43% | -69.61% |
Max Drawdown (10Y)Largest decline over 10 years | -99.24% | -33.92% | -65.32% |
Current DrawdownCurrent decline from peak | -100.00% | -1.58% | -98.42% |
Average DrawdownAverage peak-to-trough decline | -94.69% | -10.70% | -83.99% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.50% | 2.14% | +25.36% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Lisata Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Lisata Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LSTA relative to other companies in the Biotechnology industry. Currently, LSTA has a P/S ratio of 51.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LSTA in comparison with other companies in the Biotechnology industry. Currently, LSTA has a P/B value of 0.8. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with LSTA
Add Lisata Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with LSTA